Matinas BioPharma Announces Executive and Board Changes

Ticker: MTNB · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1582554

Matinas Biopharma Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyMatinas Biopharma Holdings, Inc. (MTNB)
Form Type8-K
Filed DateOct 24, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: executive-changes, board-changes, personnel

TL;DR

Matinas BioPharma shakes up exec team and board, names new CMO.

AI Summary

Matinas BioPharma Holdings, Inc. announced on October 23, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Terry L. Horgan has been appointed as the new Chief Medical Officer, and the company has entered into a new employment agreement with its Chief Executive Officer, Gregory L. Weinhoff.

Why It Matters

These executive and board changes could signal a shift in the company's strategic direction or operational focus, potentially impacting its future development and market performance.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

  • Matinas BioPharma Holdings, Inc. (company) — Registrant
  • Dr. Terry L. Horgan (person) — Appointed Chief Medical Officer
  • Gregory L. Weinhoff (person) — Chief Executive Officer
  • October 23, 2024 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Terry L. Horgan has been appointed as the new Chief Medical Officer.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is October 23, 2024.

What is the exact name of the registrant?

The exact name of the registrant is Matinas BioPharma Holdings, Inc.

In which state was Matinas BioPharma Holdings, Inc. incorporated?

Matinas BioPharma Holdings, Inc. was incorporated in Delaware.

What is the principal executive office address of Matinas BioPharma Holdings, Inc.?

The principal executive office address is 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.

Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-10-23 18:00:08

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: October 23, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.